. Show Affiliations »
Abstract
Entities: Disease
Mesh： See more » Antifibrinolytic Agents/bloodEchocardiographyFibrin Fibrinogen Degradation Products/analysisFibrinolytic Agents/administration & dosageFibrinolytic Agents/therapeutic useFollow-Up StudiesHeparin/administration & dosageHeparin/therapeutic useHumansOxygen/bloodPulmonary Embolism/diagnosisPulmonary Embolism/drug therapyPulmonary Embolism/therapyRetrospective StudiesThromboembolism/diagnosisThromboembolism/drug therapyThromboembolism/therapyThrombolytic TherapyThrombophlebitis/diagnosisThrombophlebitis/drug therapyThrombophlebitis/therapyVena Cava FiltersVentilation-Perfusion RatioVentricular Function, Right
Substances： See more » Antifibrinolytic AgentsFibrin Fibrinogen Degradation ProductsFibrinolytic Agentsfibrin fragment DHeparinOxygen
Year: 1996 PMID： 8549189 DOI： 10.1378/chest.109.1.233
Source DB: PubMed Journal: Chest ISSN： 0012-3692 Impact factor: 9.410